Loading the records…
Loading the records…
S. 2981 mandates a centralized VA Prosthetic Formulary, creating a durable government procurement channel for medical device makers. Direct beneficiaries Zimmer Biomet ($ZBH) and Stryker ($SYK) have both sold off sharply in the past week, but the bill's bipartisan momentum and committee passage signal a potential catalyst. No specific funding amount is authorized in the bill text, so actual revenue depends on subsequent contract awards.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Both $ZBH and $SYK have sold off sharply in the past week (10.73% and 3.5% respectively), unrelated to S. 2981's positive legislative progress. $ZBH at $81.47 is just 2% above its 52-week low, while $SYK at $316.04 is only 1.5% above its low. The bipartisan momentum behind this bill provides a tangible catalyst that could reverse some of this selling pressure on positive floor action. Investors should monitor Senate floor scheduling; a vote or unanimous consent passage could trigger an immediate relief rally in both names given their oversold technical conditions. However, the actual revenue impact is 12-18 months out and contingent on appropriations, so the initial move would likely be sentiment-driven rather than fundamental re-rating.
The Veterans Prosthetics Advancement and Reform Act (S. 2981) was introduced on October 7, 2025, by Senator Moran (R-KS) and has two cosponsors. It was ordered to be reported favorably out of the Senate Committee on Veterans' Affairs on March 18, 2026, and now awaits floor action. The bill's bipartisan sponsorship and committee approval suggest high passage probability in the 119th Congress (2025-2027).
The bill requires the VA Secretary to establish a "Prosthetic and Rehabilitative Items and Services Formulary," and mandates entering into contracts to support the availability of listed items. Critically, the bill text explicitly uses the word "shall" for both the formulary establishment and contract execution—this is a mandate, not an authorization. However, the bill does not specify a funding amount; it only creates the legal obligation. Actual funding for these contracts will require separate appropriations, though the mandatory language gives the VA limited discretion to delay.
Structural winners: Zimmer Biomet ($ZBH) and Stryker ($SYK) are the two largest publicly traded pure-play orthopedic and prosthetic device manufacturers with existing VA relationships. Both are positioned to win formulary contracts due to their established manufacturing scale and regulatory compliance. Smaller players like Smith+Nephew (SNN) are relevant but lack the same direct exposure to VA procurement. No specific company is named in the bill text, but the formulary mechanism directly benefits large orthopedic manufacturers.
Real market data shows both stocks have experienced significant recent selling pressure. $ZBH closed at $81.47 on April 30, 2026, down 10.73% over the past week and 9.9% over the past month, trading near the bottom of its 52-week range ($79.83-$108.29). $SYK closed at $316.04, down 3.5% weekly and 3.82% monthly, also near its 52-week low of $311.31. This selloff appears unrelated to S. 2981 (which is positive news) and more likely reflects broader healthcare sector rotation or company-specific headwinds.
Timeline: The bill has cleared committee and awaits floor action in the Senate. Given bipartisan sponsorship and the relatively non-controversial nature of improving veteran prosthetic care, passage this session is likely. If enacted, the VA would need 12-18 months to develop and publish the formulary and begin competitive contracting, meaning revenue impact for $ZBH and $SYK would likely materialize in late 2027 or early 2028.
Matched on shared policy language across AI analyses, with ticker & timing weight
MERCK SHARP & DOHME LLC: $1.8B Department of Health and Human Services Contract Vehicle
OHIO DEPARTMENT OF MEDICAID: $28.2B Department of Health and Human Services Grant
MULTIPLE RECIPIENTS: $1.2B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $2.1B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.6B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $4.0B Department of Health and Human Services Federal Award
MULTIPLE RECIPIENTS: $1.4B Department of Health and Human Services Federal Award
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →